A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections¿